Skip to content

Compare medicines

Put up to three medicines side by side. Useful for alternatives in the same class, or for seeing how two very different treatments differ.

Attribute
In shortSight-saving eye injection for wet macular degeneration.Cuts off a tumour's blood supply.
Body systemEyesCancer
Drug classAnti-VEGF injectionsTargeted antibodies
SupplyPrescription onlyPrescription only
Main usesWet age-related macular degeneration, Diabetic macular oedema, Retinal vein occlusionBowel cancer, Lung cancer, Ovarian and cervical cancer, Glioblastoma, Wet macular degeneration (off-label eye injections)
How it worksBlocks the signal that grows leaky vessels at the back of the eye.Stops tumours growing the blood vessels they need.
Starts working——
Half-life—About 20 days
Typical adult dose2 mg monthly for 3 months, then every 8–16 weeks (8 mg high-dose can extend further).5–15 mg/kg IV every 2–3 weeks depending on cancer.
FormsIntravitreal injectionIV infusion, Intravitreal injection (ophthalmic forms in some countries)
Common side effectsEye redness, Floaters, Eye painHigh blood pressure, Protein in urine, Nosebleeds, Tiredness
Serious side effectsEye infection (endophthalmitis), Retinal detachment, Raised eye pressureBowel perforation, Bleeding, Poor wound healing, Clots
Don't take if——
Alcohol——
PregnancyUsually avoidedNot recommended.Usually avoidedContraception for 6 months after.
Breastfeeding——
In use since20112004
Brand namesUnited States: Eylea, Eylea HDUnited Kingdom: EyleaIndia: EyleaUnited States: Avastin, Mvasi, ZirabevUnited Kingdom: Avastin, AlymsysIndia: Bevatas, Abevmy
Legal status——
ATC codeS01LA05L01FG01

Taken together

No interaction between these medicines is recorded in the atlas.

Open in the interaction checker